Wedmont Private Capital Has $2.16 Million Stock Holdings in Abbott Laboratories $ABT

Wedmont Private Capital decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 17.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,000 shares of the healthcare product maker’s stock after selling 4,899 shares during the quarter. Wedmont Private Capital’s holdings in Abbott Laboratories were worth $2,160,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.0%

ABT opened at $108.29 on Tuesday. The company’s 50 day moving average price is $104.74 and its two-hundred day moving average price is $100.00. The firm has a market capitalization of $187.38 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.01 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the firm posted $1.26 earnings per share. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ABT shares. Citigroup raised their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Bank of America reduced their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Piper Sandler reiterated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.